341 related articles for article (PubMed ID: 14607917)
1. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
[TBL] [Abstract][Full Text] [Related]
2. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
3. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A.
Rosato A; Zambon A; Milan G; Ciminale V; D'Agostino DM; Macino B; Zanovello P; Collavo D
Hum Gene Ther; 1997 Aug; 8(12):1451-8. PubMed ID: 9287145
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
5. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor.
Iwasaki A; Barber BH
Cancer Immunol Immunother; 1998 Jan; 45(5):273-9. PubMed ID: 9439651
[TBL] [Abstract][Full Text] [Related]
8. Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.
Mauch C; Grimm C; Meckel S; Wands JR; Blum HE; Roggendorf M; Geissler M
Vaccine; 2001 Oct; 20(1-2):170-80. PubMed ID: 11567762
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.
Vandermeulen G; Uyttenhove C; De Plaen E; Van den Eynde BJ; Préat V
Bioelectrochemistry; 2014 Dec; 100():112-8. PubMed ID: 24342164
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
11. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
12. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
13. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
14. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells.
Luo L; Chapoval AI; Flies DB; Zhu G; Hirano F; Wang S; Lau JS; Dong H; Tamada K; Flies AS; Liu Y; Chen L
J Immunol; 2004 Nov; 173(9):5445-50. PubMed ID: 15494491
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
16. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
17. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
[TBL] [Abstract][Full Text] [Related]
18. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
19. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
20. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
